An interventional study of MetFORMIN 500 Mg Oral Tablet and GlyBURIDE 2.5 MG Oral Tablet in Gestational Diabetes Mellitus in Pregnancy, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Assiut University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.
Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 with no phase, and was the 38th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–50 · Women only
Anna Stanhewicz, PhD · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 16 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 112 across the 39 interventional studies. Of the 23 that completed or were terminated, 7 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 39 has an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Assiut University has 6 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
1 of the studies testing metformin in Diabetes, Gestational that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948825George Washington UniversityEffectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies testing metformin in Diabetes, Gestational, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare the maternal, fetal, and neonatal outcomes associated with the use of metformin versus glyburide for managing gestational diabetes.
The objective is to assess the safety and effectiveness profiles of both medications as potential alternatives to initiating insulin therapy.
Primary Outcome: treatment failure is defined as the initiation of insulin due to failure of glycemic control (more than 10% of high values using 4-point glucose checks) or side effects.
Secondary Outcomes:
Maternal:
Fetal and neonatal:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with pre-gestational diabetes.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin (500 to 2000 mg orally)
Drug: MetFORMIN 500 Mg Oral Tablet
Glyburide (2.5 mg to 20 mg orally)
Drug: GlyBURIDE 2.5 MG Oral Tablet
Metformin (500 to 2000 mg orally)
Glyburide (2.5 mg to 20 mg orally)
Treatment failure
Initiation of insulin due to failure of glycemic control (more than 10% of high values using 4-point glucose checks) or side effects
Time frame: From 28 weeks till 41 weeks of pregnancy
Incidence of maternal hypoglycemia
Incidence of blood glucose levels below 4 mmol/L during the period of treatment
Time frame: From 28 weeks till 41 weeks of pregnancy
Significant side effects
Incidence of maternal significant side effects requiring cessation of treatment (gastrointestinal side effects)
Time frame: From 28 weeks till 41 weeks of pregnancy
Fetal macrosomia (large for gestational age)
Incidence of fetuses growing above the 90th percentile on third ultrasound scan using customised growth chart
Time frame: 32 weeks of gestation to onset of labour
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jan 2025; primary completion for Dec 2025, 11 months later.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 11 months is below that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metformin · Glyburide